BioSpace News Archive

Blade Therapeutics announced that it has nominated a clinical development candidate for its lead program focused on small molecule inhibitors that selectively target certain intracellular cysteine proteases.

Phytecs, Inc., a biotechnology company exploring potential therapies that target the body’s endocannabinoid system (ECS) to treat disease, today announced the addition of new members to the company’s Scientific Advisory Board.

10x Genomics, a company focused on enabling the mastery of biology by accelerating genomic discovery, this week will launch new products for their Chromium Immune Repertoire Profiling Solution utilizing massively-parallel single cell RNA-seq (scRNA-seq) to sequence paired V(D)J B-cell receptors, together with unbiased gene expression for reading the immune-repertoire along with cell phenotype.

Synspir announced initiation of a Phase 1a first-in-human, multi-center study of SNSP113, its lead drug candidate, in development for use in pulmonary complications of cystic fibrosis (CF).

Revance Therapeutics announced it has completed enrollment of patients in the Company’s Phase 2 program investigating the use of DaxibotulinumtoxinA for Injection (RT002) for the management of plantar fasciitis.

Pharmaceutical Product Development is sponsoring Walk MS: Austin as part of the PPD Heroes initiative to raise awareness about the life-changing impact of clinical research for patients.

Tetra Bio-Pharma Signs Agreement With Partner Aphria to Start Promoting Rx Princeps, Its Medical Cannabis Blend, under ACMPR OTTAWA, ONTARIO -- (Marketwired) -- Oct 18, 2017 -- Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) ( TSX VENTURE : TBP )( OTCQB : TBPMF ), a global leader in cannabinoid-based drug development and discovery, today announced that it will start promoting a co-developed medical cannabis blend product under Access to Cannabis for Medical Purposes Regula

Therapix signed an agreement with Assuta Medical Center, the largest hospital network and private healthcare provider in Israel, to conduct a Phase IIa, sponsor-initiated trial.

Last month Maxogen Group successfully closed its current financing round.

Caris Life Sciences announced today the John Wayne Cancer Institute has joined the company’s Precision Oncology Alliance (POA).